CLINICAL TRIAL: P1025 PERINATAL CORE PROTOCOL VERSION 10

临床试验：P1025 围产期核心方案版本 10

• 批准号: 8356654
• 负责人: William Thomas Shearer
• 金额: $ 11.17万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-12-01 至 2011-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8356654
• 关键词: Clinical Research; Clinical Trials; Counseling; Development; Funding; Grant; HIV-1; Intervention; Medical; National Center for Research Resources; Perinatal; Pregnant Women; Principal Investigator; Protocols documentation; Research; Research Infrastructure; Resources; Risk; Source; Testing; United States; United States National Institutes of Health; Vertical Disease Transmission; cost

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Approximately 500-600 cases of vertical transmission of human immunodeficiency virus type 1 (HIV) now occur annually in the United States. The dramatic reduction in vertical transmission rates in the United States is related to several factors, including: increased provision and acceptance of voluntary counseling and HIV testing of pregnant women, improvements in the medical management of HIV-infected pregnant women, and the development and increased acceptance of interventions to decrease the risk of mother-to-child transmission of HIV.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 目前，美国每年大约发生 500-600 例人类免疫缺陷病毒 1 型 (HIV) 垂直传播病例。美国垂直传播率的大幅下降与多种因素有关，包括：增加对孕妇的自愿咨询和艾滋病毒检测的提供和接受程度、对感染艾滋病毒的孕妇的医疗管理的改进以及发展和提高艾滋病毒感染孕妇的医疗管理水平。接受降低艾滋病毒母婴传播风险的干预措施。